This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tai, S.-K. Articles by Mao, L. Search for Related Content PubMed PubMed Citation Articles by Tai, S.-K. Articles by Mao, L.

Loss of Fhit Expression in Head and Neck Squamous Cell Carcinoma and Its Potential Clinical Implication

Departments of ¹ Thoracic/Head and Neck Medical Oncology, ² Radiation Oncology, ³ Pathology, and ⁴ Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and ⁵ Department of Otolaryngology, National Yang Ming University, Taipei Veteran General Hospital, Taipei, Taiwan

Purpose: Abnormalities of FHIT, a candidate tumor suppressor gene, have frequently been found in multiple malignancies, including head and neck squamous cell carcinoma (HNSCC). To define its role in HNSCC treated with surgery and postoperative radiotherapy (PORT), the Fhit protein expression status was investigated in 80 patients enrolled in a prospective Phase III clinical trial addressing the dose and fractionation regimen of PORT.

Experimental Design: Immunohistochemical staining of HNSCC tissue sections for Fhit expression was performed. The Fhit expression status was correlated with the clinicopathological characteristics and clinical course. The median follow-up duration was 4.9 years.

Results: Loss of Fhit expression was found in 52 of the 80 study patients (65%). There was not a significant association between Fhit expression and clinical characteristics. Patients whose tumor exhibited negative Fhit expression had a significantly worse 5-year overall survival duration [hazard ratio = 0.49; 95% confidence interval, 0.23–1.03; P = 0.05 (log-rank test)] than did those whose tumor exhibited positive Fhit expression. One third of the patients with a Fhit-negative tumor had distant metastasis during the follow-up period. Paradoxically, patients classified as high risk who had a Fhit-negative tumor experienced locoregional recurrence less often (18%) than did high-risk patients who had a Fhit-positive tumor (33%).

Conclusions: Loss of Fhit expression is a poor prognostic indicator in patients with HNSCC. However, tumors lacking Fhit expression may be more sensitive to PORT and therefore more susceptible to locoregional control.

This article has been cited by other articles:

				O. Kujan, R. Oliver, L. Roz, G. Sozzi, N. Ribeiro, R. Woodwards, N. Thakker, and P. Sloan Fragile Histidine Triad Expression in Oral Squamous Cell Carcinoma and Precursor Lesions. Clin. Cancer Res., November 15, 2006; 12(22): 6723 - 6729. [Abstract] [Full Text] [PDF]